A bug in the resistance to EGFR inhibitors: is there a role for Mycoplasma and cytidine deaminase in reducing the activity of osimertinib in lung cancer patients?

TY - JOUR

T1 - A bug in the resistance to EGFR inhibitors: is there a role for Mycoplasma and cytidine deaminase in reducing the activity of osimertinib in lung cancer patients?

AU - Leonetti, Alessandro

AU - Carbone, Daniela

AU - Gregori, Alessandro

AU - Tiseo, Marcello

AU - Peters, Godefridus J.

AU - Deng, Dongmei

AU - Giovannetti, Elisa

N1 - Funding Information: MT has been on advisory boards and received speakers’ fees for Astra-Zeneca, Pfizer, Eli-Lilly, BMS, Novartis, Roche, MSD, Boehringer Ingelheim, Otsuka, Takeda, and Pierre Fabre. MT has received research grants from Astra-Zeneca and Boehringer Ingelheim. AL received speakers’ fees for Astra-Zeneca. Funding Information: AL and MT are supported by the AIRC-IG grant# 20,074, AG and EG are supported by the KWF Grant#19,571, GJP and EG are supported by the Polish National Science Center Grant#2018/31/B/NZ7/02,909, DD and EG are supported by Cancer Center Amsterdam Grants 2016 and 2018, EG is supported by the AIRC-IG grant#24,444.

PY - 2021/10

Y1 - 2021/10

UR - http://www.scopus.com/inward/record.url?scp=85104867980&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85104867980&partnerID=8YFLogxK

U2 - 10.1007/s00432-021-03647-x

DO - 10.1007/s00432-021-03647-x

M3 - Comment / Letter to the editor

C2 - 33900435

AN - SCOPUS:85104867980

SN - 0171-5216

VL - 147

SP - 3135

EP - 3137

JO - Journal of Cancer Research and Clinical Oncology

JF - Journal of Cancer Research and Clinical Oncology

IS - 10

ER -